R（+）-SKF-81297氢溴酸盐 | 253446-15-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯氮卓类
• 中文名称: R（+）-SKF-81297氢溴酸盐
• 英文名称: R-(+)-SKF 81297 hydrobromide
• 英文别名: R(+)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide；(+)-SKF81297；R(+)-SKF-81297 hydrobromide；(5R)-9-chloro-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol;hydrobromide
• CAS: 253446-15-0
• 化学式: BrH*C₁₆H₁₆ClNO₂
• 分子量: 370.673
• InChiKey: RMIJGBMRNYUZRG-BTQNPOSSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.61
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52.5
• 氢给体数：
  4
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  碘甲烷-13C 、 R（+）-SKF-81297氢溴酸盐 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.08h， 以28%的产率得到R-[N-methyl-13C]SKF 82957
  参考文献：
  名称：

  Synthesis ofR-[N-methyl-13C]SKF 82957 from [13C]methyl iodide and [13C]methyl triflate

  摘要：

  DOI：

  10.1002/1099-1344(200006)43:7<701::aid-jlcr355>3.0.co;2-w

文献信息

• Gillies; Luthra; Brady, Journal of labelled compounds and radiopharmaceuticals, 1999, vol. 42, # SUPPL. 1, p. S462-S464
  作者：Gillies、Luthra、Brady、Brooks

  DOI：——

  日期：——
• DaSilva, J. N.; Burrow, T. E.; Wilson, A. A., Journal of labelled compounds and radiopharmaceuticals, 2001, vol. 44, p. S983 - S985
  作者：DaSilva, J. N.、Burrow, T. E.、Wilson, A. A.、Houle, S.

  DOI：——

  日期：——
• [EN] TREATMENT OF DYSKINESIA<br/>[FR] TRAITEMENT DE LA DYSKINESIE
  申请人：——

  公开号：WO2002007766A2

  公开（公告）日：2002-01-31

  The present invention relates to compounds, which enhance D5-dopamine receptor activity, or activation (e.g. selective D5-dopanime receptor agonists), that may be used in the treatment of dyskinesia.
• [EN] COMBINATION MEDICINE FOR TREATMENT OF DEPRESSION<br/>[FR] COMBINAISON MÉDICINALE POUR LE TRAITEMENT DE LA DÉPRESSION
  申请人：UNIV KURUME

  公开号：WO2012127871A1

  公开（公告）日：2012-09-27

  The present invention provides a combination medicine for treatment of depression, comprising a combination of (A1) an antidepressant and either (B1) a dopamine D1 receptor agonist or (C1) a dopamine D1 receptor antagonist; and a method for screening for an antidepressant that in combination with a dopamine D1 receptor agonist provides an improvement in treatment of depression, the method comprising the steps of: administering, to a mammal, (A2) a compound having an antidepressant action and (B1)a dopamine D1 receptor agonist, and detecting a greater increase in depression-related gene expression, dopamine D1 receptor expression and/or dopamine D1 receptor signaling in comparison with the case where (A2) the compound having an antidepressant action or (B1) the dopamine D1 receptor agonist is administered.